

Wen Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/662892/publications.pdf>

Version: 2024-02-01

49
papers

1,107
citations

567281

15
h-index

434195

31
g-index

53
all docs

53
docs citations

53
times ranked

1739
citing authors

#	ARTICLE	IF	CITATIONS
1	CSH guidelines for the diagnosis and treatment of drug-induced liver injury. <i>Hepatology International</i> , 2017, 11, 221-241.	4.2	206
2	Rutin ameliorates obesity through brown fat activation. <i>FASEB Journal</i> , 2017, 31, 333-345.	0.5	151
3	New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. <i>Hepatology</i> , 2017, 65, 1438-1450.	7.3	125
4	Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. <i>Military Medical Research</i> , 2020, 7, 28.	3.4	58
5	Two-step fitness selection for intra-host variations in SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110205.	6.4	38
6	Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. <i>Virology Journal</i> , 2015, 12, 109.	3.4	36
7	Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4 ⁺ CD25 ⁺ CD69 ⁺ subset proliferation. <i>Drug Design, Development and Therapy</i> , 2016, 10, 443.	4.3	35
8	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1860-1867.	2.8	32
9	Glecaprevir and pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 839-849.	8.1	32
10	On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. <i>Liver International</i> , 2018, 38, 1045-1054.	3.9	29
11	Genomic surveillance of COVID-19 cases in Beijing. <i>Nature Communications</i> , 2020, 11, 5503.	12.8	26
12	COVID-19 reinfection in the presence of neutralizing antibodies. <i>National Science Review</i> , 2021, 8, nwab006.	9.5	24
13	Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 303.	5.4	20
14	Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. <i>Journal of Viral Hepatitis</i> , 2019, 26, 576-585.	2.0	19
15	Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. <i>Medical Science Monitor</i> , 2020, 26, e920350.	1.1	19
16	A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. <i>Hepatology International</i> , 2012, 6, 441-448.	4.2	17
17	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 61-69.	3.1	17
18	The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110486.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 37498.	3.3	13
20	Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. <i>Advances in Therapy</i> , 2018, 35, 218-231.	2.9	13
21	Reactivation of SARS-CoV-2 infection following recovery from COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 620-627.	4.1	12
22	Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 745-757.	2.7	11
23	Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study. <i>Annals of Hepatology</i> , 2017, 16, 123-132.	1.5	10
24	Infection and disease spectrum in individuals with household exposure to SARS-CoV-2: A family cluster cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 3033-3046.	5.0	10
25	Oral delivery of a <i>Lactococcus lactis</i> expressing extracellular TGF β 2R2 alleviates hepatic fibrosis. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 6007-6018.	3.6	10
26	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211080.	2.5	10
27	Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report. <i>BMC Gastroenterology</i> , 2018, 18, 142.	2.0	9
28	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 415-423.	2.0	9
29	Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges. <i>BioMed Research International</i> , 2020, 2020, 1-7.	1.9	8
30	Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 634266.	3.5	8
31	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-7.	1.4	8
32	Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. <i>Liver International</i> , 2022, 42, 1803-1813.	3.9	7
33	High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 767-774.	2.8	6
34	Sex differences in clinical characteristics and risk factors for disease severity of hospitalized patients with COVID-19. <i>MedComm</i> , 2021, 2, 247-255.	7.2	6
35	Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. <i>World Journal of Gastroenterology</i> , 2018, 24, 1361-1372.	3.3	6
36	Cell culture-adaptive mutations in hepatitis C virus promote viral production by enhancing viral replication and release. <i>World Journal of Gastroenterology</i> , 2018, 24, 1299-1311.	3.3	5

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis. <i>Hepatology International</i> , 2021, 15, 1318-1327.	4.2	5
38	Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. <i>Scientific Reports</i> , 2017, 7, 10289.	3.3	4
39	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. <i>Scandinavian Journal of Public Health</i> , 2020, 48, 233-239.	2.3	4
40	Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with LSM. <i>Liver International</i> , 2021, 41, 369-377.	3.9	4
41	On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α therapy. <i>Journal of Medical Virology</i> , 2019, 91, 1499-1509.	5.0	3
42	Acute-on-Chronic Liver Failure in Pregnant Patients with Chronic Hepatitis B: A Retrospective Observational Case Series Study. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-8.	1.5	3
43	Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e25327.	1.0	3
44	Early and consecutive RT-PCR tests with both oropharyngeal swabs and sputum could improve testing yield for patients with COVID-19: An observation cohort study in China. <i>International Journal of Infectious Diseases</i> , 2021, 107, 242-246.	3.3	3
45	Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 885.	2.9	3
46	Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. <i>Hepatology International</i> , 2021, 15, 82-92.	4.2	3
47	Transmission dynamics of COVID-19 among index case family clusters in Beijing, China. <i>Epidemiology and Infection</i> , 2021, 149, e74.	2.1	2
48	Efficacy and Safety of All-oral Emetasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	1.4	2
49	The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism. <i>Analytical Cellular Pathology</i> , 2019, 2019, 1-8.	1.4	1